The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308

✍ Scribed by Lilian Soto; Francisca Sabugo; Diego Catalan; Pamela Wurmann; Tomás Cermenatti; Héctor Gatica; Octavio Aravena; Lorena Salazar; Juan Carlos Aguillón; Miguel Cuchacovich

• Publisher: Springer
• Year: 2011
• Tongue: English
• Weight: 112 KB
• Volume: 30
• Category: Article
• ISSN: 0770-3198
• DOI: 10.1007/s10067-011-1679-4